Avila Therapeutics

Avila developed medicines with the potential to improve patient outcomes in a fundamentally new way. Using a proprietary platform, Avila generated novel covalent drugs that bound irreversibly to specific disease-causing proteins, thereby 'silencing' them and eradicating the corresponding disease. The company was acquired by Celgene for up to $925 million in January 2012.